It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The aberrant gain of DNA methylation at CpG islands is frequently observed in colorectal tumours and may silence the expression of tumour suppressors such as MLH1. Current models propose that these CpG islands are targeted by de novo DNA methyltransferases in a sequence-specific manner, but this has not been tested. Using ectopically integrated CpG islands, here we find that aberrantly methylated CpG islands are subject to low levels of de novo DNA methylation activity in colorectal cancer cells. By delineating DNA methyltransferase targets, we find that instead de novo DNA methylation activity is targeted primarily to CpG islands marked by the histone modification H3K36me3, a mark associated with transcriptional elongation. These H3K36me3 marked CpG islands are heavily methylated in colorectal tumours and the normal colon suggesting that de novo DNA methyltransferase activity at CpG islands in colorectal cancer is focused on similar targets to normal tissues and not greatly remodelled by tumourigenesis.
Aberrant gain of DNA methylation at CpG islands is frequently observed in colorectal tumours. Here the authors use ectopically integrated CpG islands in colorectal cancer cells and find that aberrantly methylated CpG islands are subject to low levels of de novo DNA methylation, and that instead de novo DNA methylation activity is targeted primarily to CpG islands marked by the histone modification H3K36me3.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 University of Edinburgh, MRC Human Genetics Unit, IGMM, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
2 University of Edinburgh, MRC Human Genetics Unit, IGMM, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); University of Edinburgh, CRUK Edinburgh Centre, IGMM, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
3 University of Edinburgh, Edinburgh Clinical Research Facility, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
4 University of Edinburgh, CRUK Edinburgh Centre, IGMM, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
5 University of Edinburgh, CRUK Edinburgh Centre, IGMM, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); Queen Mary University of London, Centre for Tumour Biology, Barts Cancer Institute, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133)